The impact of regular bisoprolol on the response to salbutamol in asthma: A double-blind randomized placebo-controlled crossover trial
- PMID: 33043552
- DOI: 10.1111/resp.13955
The impact of regular bisoprolol on the response to salbutamol in asthma: A double-blind randomized placebo-controlled crossover trial
Abstract
Background and objective: Non-selective beta-blockers impair the bronchodilator response to beta2 -agonists. Cardio-selective beta1 -blockers are less likely to cause this effect, yet they remain relatively contraindicated in asthma. We investigated whether the response to salbutamol is impaired during cardio-selective beta1 -blocker treatment in people with asthma.
Methods: A random-order, double-blind, placebo-controlled, non-inferiority, crossover study was conducted comparing up to 5 mg bisoprolol daily for 2 weeks with matching placebo, with an open-label extension of up to 10 mg bisoprolol daily. After each treatment period, mannitol was inhaled to induce bronchoconstriction with a 15% fall in forced expiratory volume in 1 s (FEV1 ). Immediately after mannitol challenge, salbutamol (100, 100 and 200 μg) was administered via spacer at 5-min intervals with repeated FEV1 measures. The FEV1 recovery with salbutamol was measured as an area under recovery curve (AUC). Based on earlier research, a clinically relevant non-inferiority limit of a 30% reduction in the AUC was set.
Results: A total of 19 adults with mild asthma and positive inhaled mannitol challenge completed the study. Adjusting for the FEV1 fall induced by mannitol and treatment sequence, the mean AUC response to salbutamol after bisoprolol was 5% lower than after placebo, with a one-sided 95% confidence interval (CI) of 26% lower. Thirteen participants completed the open-label extension up to 10 mg bisoprolol daily with mean AUC 11% higher after bisoprolol with a 95% CI of 5% lower.
Conclusion: The bronchodilator response to rescue salbutamol after mannitol-induced bronchoconstriction is non-inferior during regular treatment with the cardio-selective beta1 -blocker, bisoprolol, compared to placebo.
Clinical trial registration: ACTRN12618000306213 at https://www.anzctr.org.au.
Keywords: adrenergic beta-antagonists beta-blocker; adrenergic beta2-receptor agonists; asthma; bisoprolol; salbutamol.
© 2020 Asian Pacific Society of Respirology.
Comment in
-
Cardiac-specific beta-blockers and asthma: An end to fear?Respirology. 2021 Mar;26(3):216-217. doi: 10.1111/resp.13979. Epub 2020 Nov 19. Respirology. 2021. PMID: 33210754 No abstract available.
Similar articles
-
The safety of cardioselective β1-blockers in asthma: literature review and search of global pharmacovigilance safety reports.ERJ Open Res. 2021 Mar 1;7(1):00801-2020. doi: 10.1183/23120541.00801-2020. eCollection 2021 Jan. ERJ Open Res. 2021. PMID: 33681344 Free PMC article. Review.
-
Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.Thorax. 2001 Jul;56(7):529-35. doi: 10.1136/thorax.56.7.529. Thorax. 2001. PMID: 11413351 Free PMC article. Clinical Trial.
-
Bronchodilator tolerance: the impact of increasing bronchoconstriction.Eur Respir J. 2003 May;21(5):810-5. doi: 10.1183/09031936.03.00067503. Eur Respir J. 2003. PMID: 12765426 Clinical Trial.
-
Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial.Respir Res. 2005 Sep 16;6(1):107. doi: 10.1186/1465-9921-6-107. Respir Res. 2005. PMID: 16168062 Free PMC article. Clinical Trial.
-
A meta-analysis of the influence of ADRB2 genetic polymorphisms on albuterol (salbutamol) therapy in patients with asthma.Br J Clin Pharmacol. 2021 Apr;87(4):1708-1716. doi: 10.1111/bcp.14570. Epub 2020 Oct 25. Br J Clin Pharmacol. 2021. PMID: 32986886
Cited by
-
An updated insight into the effect of β-adrenergic receptor antagonists (β-blockers) on respiratory function in asthma patients: a systematic review and meta-analysis.Front Physiol. 2025 Jul 25;16:1582740. doi: 10.3389/fphys.2025.1582740. eCollection 2025. Front Physiol. 2025. PMID: 40786074 Free PMC article.
-
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences.Drugs. 2024 Oct;84(10):1251-1273. doi: 10.1007/s40265-024-02086-5. Epub 2024 Sep 26. Drugs. 2024. PMID: 39327397 Free PMC article. Review.
-
Abdominal aortic aneurysm growth rates in patients undergoing local ultrasound surveillance.Ultrasound. 2023 Feb;31(1):23-32. doi: 10.1177/1742271X221093751. Epub 2022 Jun 1. Ultrasound. 2023. PMID: 36794114 Free PMC article.
-
Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease.Cardiovasc Drugs Ther. 2022 Oct;36(5):959-971. doi: 10.1007/s10557-021-07205-y. Epub 2021 Jun 9. Cardiovasc Drugs Ther. 2022. PMID: 34106365 Free PMC article. Review.
-
The safety of cardioselective β1-blockers in asthma: literature review and search of global pharmacovigilance safety reports.ERJ Open Res. 2021 Mar 1;7(1):00801-2020. doi: 10.1183/23120541.00801-2020. eCollection 2021 Jan. ERJ Open Res. 2021. PMID: 33681344 Free PMC article. Review.
References
REFERENCES
-
- Harries AD. Beta-blockade in asthma. Br. Med. J. (Clin. Res. Ed.) 1981; 282: 1321.
-
- Hugues FC, Matte JC, Le Jeunne C, Salem A. Effects of beta-adrenoceptors blocking eye drops in patients with chronic bronchitis. Therapie 1992; 47: 211-5.
-
- McNeill RS, Ingram CG. Effect of propranolol on ventilatory function. Am. J. Cardiol. 1966; 18: 473-5.
-
- Raine JM, Palazzo MG, Kerr JH, Sleight P. Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane. Br. Med. J. (Clin. Res. Ed.) 1981; 282: 548-9.
-
- Williams IP, Millard FJ. Severe asthma after inadvertent ingestion of oxprenolol. Thorax 1980; 35: 160.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical